NCT01460342已完成3 期
A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Parallel-Design, Study to Evaluate the Efficacy and Safety of Tadalafil Once-a-day Dosing for 12 Weeks in Asian Men With Signs and Symptoms of Benign Prostatic Hyperplasia
适应症
干预措施
相关药物
试验速览
- 阶段
- 3 期
- 状态
- 已完成
- 入组人数
- 610
- 试验地点
- 1
- 主要终点
- Change From Baseline in Total Score of International Prostate Symptom Score (IPSS) at 12 Weeks
研究概览
简要总结
This is a phase 3, randomized, double-blind, placebo-controlled, parallel-design, multinational study to evaluate the efficacy and safety of tadalafil once-a-day dosing for 12 weeks in Asian men with signs and symptoms of benign prostatic hyperplasia.
详细描述
Tadalafil is being investigated as a treatment for men with signs and symptoms of benign prostatic hyperplasia [BPH; also referred to as urinary disturbance or BPH-LUTS (BPH-lower urinary tract symptoms)] in Japan and overseas. Overseas studies and the Japanese dose-finding study LVIA (NCT00783094) identified tadalafil 5 mg once-daily as the recommended dose. The long-term safety and maintenance of effect was confirmed in the open-label extension of study LVIA. The risk-benefit profile was further studied in the Asian study LVHB (NCT00861757).
This study, LVJF, is to confirm the efficacy and safety of tadalafil 5 mg once-daily in Asian men with BPH-LUTS.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
入排标准
- 年龄范围
- 45 Years 至 —（Adult, Older Adult）
- 性别
- Male
- 接受健康志愿者
- 否
入选标准
- •Present with benign prostatic hyperplasia (BPH; also referred to as BPH-LUTS), based on the disease diagnostic criteria, at study entry.
- •Provide signed informed consent at study entry.
- •Have BPH-LUTS with a Total International Prostate Symptom Score (IPSS) of ≥13 at beginning of placebo lead-in period.
- •Have bladder outlet obstruction of intermediate severity as defined by a urinary peak flow rate (Qmax) of ≥4 to ≤15 milliliters per second (mL/sec) [from a prevoid total bladder volume (assessed by ultrasound) of ≥150 to ≤550 milliliters (mL) and a minimum voided volume of 125 mL] at beginning of placebo lead-in period.
- •Have prostate volume ≥20 mL estimated by transabdominal or transrectal ultrasound at study entry.
- •Agree not to use any other approved or experimental pharmacologic BPH, erectile dysfunction (ED) and/or overactive bladder (OAB) treatments, including alpha-blockers, 5-alpha reductase inhibitors (5-ARIs), phosphodiesterase type 5 (PDE5) inhibitors, or herbal preparations at any time during the study.
- •Have not taken the following treatments within the indicated duration:
- •Finasteride therapy for at least 3 months prior to beginning of placebo lead-in period.
- •Dutasteride therapy for at least 6 months prior to beginning of placebo lead-in period.
- •Anti-androgenic hormone therapy at least 12 months prior to beginning of placebo lead-in period.
- •All other BPH therapy (including herbal preparations) for at least 4 weeks prior to beginning of placebo lead-in period.
- •ED therapy for at least 4 weeks prior to beginning of placebo lead-in period.
- •OAB therapy for at least 4 weeks prior to beginning of placebo lead-in period.
- •Demonstrate compliance with study drug administration requirements during the placebo lead-in period by administering ≥70% of prescribed doses, confirmed by documentation that the participant returned ≤30% of prescribed doses at randomization.
排除标准
- •Prostate-specific antigen (PSA) >10.0 nanograms per milliliter (ng/mL) at study entry.
- •PSA ≥4.0 to ≤10.0 ng/mL at study entry, if prostate malignancy has not been ruled out to the satisfaction of an urologist.
- •Bladder postvoid residual (PVR) ≥300 mL by ultrasound determination at study entry.
- •History of any of the following pelvic conditions (checked at study entry):
- •Pelvic surgery or any other pelvic procedure, including radical prostatectomy, pelvic surgery for removal of malignancy, or bowel resection.
- •Pelvic radiotherapy.
- •Any pelvic surgical procedure on the urinary tract, including minimally invasive BPH-LUTS therapies and penile implant surgery.
- •Lower urinary tract malignancy or trauma.
- •Lower urinary tract instrumentation (including prostate biopsy) within 30 day of study entry.
- •History of urinary retention or lower urinary tract (bladder) stones within 6 months of study entry.
- •History of urethral obstruction due to stricture, valves, sclerosis, or tumor.
- •Current neurologic disease or condition associated with neurogenic bladder (for example, Parkinson's disease, multiple sclerosis) at study entry.
- •Clinical evidence of prostate cancer.
- •Clinical evidence of any of the following bladder conditions:
- •Mullerian duct cysts.
- •Atonic, decompensated, or hypocontractile bladder.
- •Detrusor-sphincter dyssynergia (contraction of the detrusor without sphincter relaxation).
- •Intravesical obstruction (for example, intravesical median lobe of the prostate).
- •Interstitial cystitis.
- •Clinical evidence of any of the following urinary tract conditions at study entry:
- •Urinary tract infection.
- •Urinary tract inflammation (including prostatitis). Urinary tract infection/inflammation is defined as a positive result for leukocyte esterase from a urine dipstick or >5 white blood cells (WBCs) per high-powered field on urinalysis from a centrifuged, clean-catch, midstream urine specimen.
- •Current antibiotic therapy for urinary tract infection.
- •Clinically significant microscopic hematuria as determined by an urologist.
- •History of significant renal insufficiency, defined as receiving renal dialysis or having an estimated creatinine clearance <30 milliliters per minute (mL/min) at study entry, as calculated by the central laboratory using the Cockcroft-Gault formula.
- •Clinical evidence of severe hepatic impairment [aspartate transaminase (AST) or alanine transaminase (ALT) >3-fold of the upper limit of normal range] at study entry.
- •History of any of the following cardiac conditions (checked at study entry):
- •Angina requiring treatment with long-acting nitrates.
- •Angina requiring treatment with short-acting nitrates within 90 days of study entry.
- •Unstable angina within 90 days of study entry.
- •Positive cardiac stress test without documented evidence of subsequent, effective cardiac intervention.
- •History of any of the following coronary conditions within 90 days of study entry:
- •Myocardial infarction.
- •Coronary artery bypass graft surgery.
- •Percutaneous coronary intervention (for example, angioplasty or stent placement).
- •Any evidence of heart disease [New York Heart Association (NYHA) ≥Class III] within 6 months of study entry.
- •Systolic blood pressure >160 or <90 millimeters of mercury (mm Hg) or diastolic blood pressure >100 or <50 mm Hg at study entry (if stress is suspected, retest under basal conditions), or malignant hypertension.
- •Glycosylated hemoglobin (HbA1c) >9% at study entry.
- •Scheduled or planned surgery (or any procedure requiring general, spinal, or epidural anesthesia) during the course of the study.
- •History of significant central nervous system injuries (including stroke or spinal cord injury) within 6 months of study entry.
- •History of drug, alcohol, or substance abuse within 6 months of study entry.
- •Current treatment with nitrates, androgens, antiandrogens, estrogens, luteinizing hormone-releasing hormone agonists/antagonists, or anabolic steroids at study entry.
- •Current systemic treatment with any of the following:
- •Potent cytochrome P450 3A4 (CYP3A4) inhibitors, such as ketoconazole or ritonavir.
- •CYP3A4 inducers such as rifampicin.
- •Known or suspected to be hypersensitive to tadalafil, or any study drug components.
- •Any conditions that would interfere with a participant's ability to provide informed consent or comply with study instructions, would place participant at increased risk, or might confound the interpretation of the study results.
- •Previously completed or withdrawn from this study or any other study investigating tadalafil.
- •Received treatment within the last 30 days with a drug or device that has not received regulatory approval for any indications at the time of informed consent. Participants who have been screen failures in previous studies may be eligible.
研究组 & 干预措施
Placebo
Placebo Comparator
Following the 4-week placebo lead-in period, this arm will consist of a 12-week placebo treatment period involving 2 x 2.5-milligram (mg) tadalafil placebo tablets taken orally once daily.
干预措施: Placebo (Drug)
Tadalafil
Experimental
Following the 4-week placebo lead-in period, this arm will consist of a 12-week treatment period involving 2 x 2.5-mg tadalafil tablets taken orally once daily.
干预措施: Tadalafil (Drug)
Tadalafil
Experimental
Following the 4-week placebo lead-in period, this arm will consist of a 12-week treatment period involving 2 x 2.5-mg tadalafil tablets taken orally once daily.
干预措施: Placebo (Drug)
结局指标
主要结局
Change From Baseline in Total Score of International Prostate Symptom Score (IPSS) at 12 Weeks
时间窗: Baseline, 12 weeks
The IPSS Total Score was the sum of Questions 1 through 7 in the IPSS questionnaire. Each question was based on the participant's urination experiences and prostate symptoms during the last month. Scores ranged from 0 (none/no symptoms) to 5 (frequent symptoms) for an IPSS Total Score that ranged from 0 to 35; higher numerical scores represented a greater severity of symptoms. Least squares (LS) mean was based on the mixed-effect model repeated measures (MMRM) model analysis with participants as random effects, treatment, prior alpha-blocker use (yes/no), country (Japan/Korea), visit, and treatment-by-visit interaction as fixed effects, and baseline value and placebo lead-in total IPSS change as fixed covariates.
次要结局
- Change From Baseline in Total Score of International Prostate Symptom Score (IPSS)(Baseline, 4 weeks, 8 weeks)
- Patient Global Impression of Improvement (PGI-I) Scale at 12 Weeks(12 Weeks)
- Clinician Global Impression of Improvement (CGI-I) Scale at 12 Weeks(12 Weeks)
- Change From Baseline in Modified International Prostate Symptom Score (mIPSS) Score at 2 Weeks(Baseline, 2 weeks)
- Change From Baseline in the International Prostate Symptom Score (IPSS) Storage (Irritative) Subscore(Baseline, 4 weeks, 8 weeks, 12 weeks)
- Change From Baseline in the International Prostate Symptom Score (IPSS) Voiding (Obstructive) Subscore(Baseline, 4 weeks, 8 weeks, 12 weeks)
- Change From Baseline in the International Prostate Symptom Score (IPSS) Quality of Life (QoL) Index(Baseline, 4 weeks, 8 weeks, 12 weeks)
研究者
研究点 (1)
Loading locations...
相似试验
终止
3 期
A Study of Rovalpituzumab Tesirine as Maintenance Therapy Following First- Line Platinum-Based Chemotherapy in Participants With Extensive Stage Small Cell Lung Cancer (MERU)Small Cell Lung CancerNCT03033511AbbVie748
已完成
3 期
A Study to Evaluate the Efficacy and Safety of Subcutaneous Amlitelimab in Participants Aged 12 Years and Older With Moderate-to-severe Atopic Dermatitis on Background Topical CorticosteroidsDermatitis AtopicNCT06224348Sanofi643
已完成
3 期
A Study to Evaluate the Efficacy and Safety of Subcutaneous Amlitelimab Monotherapy Compared With Placebo in Participants Aged 12 Years and Older With Moderate-to-severe Atopic DermatitisDermatitis AtopicNCT06130566Sanofi601
已完成
3 期
A Study to Evaluate the Efficacy and Safety of Subcutaneous Amlitelimab Monotherapy Compared With Placebo in Participants Aged 12 Years and Older With Moderate-to-severe Atopic Dermatitis (COAST 2)Dermatitis AtopicNCT06181435Sanofi589
进行中（未招募）
3 期
A Study to Evaluate the Efficacy and Safety of Subcutaneous Amlitelimab on Background Topical Corticosteroids Therapy in Participants Aged 12 Years and Older With Moderate-to-severe AD Who Have Had an Inadequate Response to Prior Biologic Therapy or an Oral JAK InhibitorDermatitis AtopicNCT06241118Sanofi464